NIH-funded research R01 grant

Glutaminase metabolism in dendritic cells and its role in inflammation and tolerance

Official title: Determining the contribution of glutaminase-dependent metabolism ofdendritic cells to inflammatory diseases

Funded at University of Chicago · NIH-11567724 · Data updated 2026-11-12

This grant looks at how a key metabolic enzyme in dendritic cells may control whether immune cells promote inflammation or promote tolerance in allergic diseases.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Chicago
NIH-funded
Lab location1 site (Chicago, United States)
Project startJune 13, 2026
Project endJune 30, 2030
Funding year2026
Award (this year)$648,688
NIH project number7R01AI192909-02
Project IDNIH-11567724 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are patients with allergic diseases in whom future translational work could explore metabolism-based therapies; at this stage, the study is preclinical.

Less likely to help

Patients with allergic diseases may not directly benefit during this preclinical phase, as results come from mouse models and cellular studies.

What this research studies

Dendritic cells help decide whether the immune system fights or tolerates threats. The project will study how the metabolism of glutamine, via the enzyme glutaminase, influences dendritic cell function and antigen presentation. Using mouse models where glutaminase is missing in dendritic cells, researchers will examine changes in how DCs mature, activate T cells, and shape inflammation or tolerance. The goal is to uncover metabolic checkpoints that could be targeted to treat allergic conditions by steering immune responses toward tolerance.

Why it matters

Potential benefit: If successful, findings could lead to new approaches that dampen allergic inflammation by reprogramming immune cell metabolism.

How similar studies have gone: Previous work shows that DC metabolism influences antigen presentation and inflammation, supporting the plausibility of targeting glutaminase to modulate immune responses.

Where this research is happening

  • University of Chicago
    Chicago, United States
    Active

Researchers

  • Principal investigator: Mogilenko, Denis — University of Chicago
  • Study coordinator: Mogilenko, Denis

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.